title: C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.
authors.forename: Stephan
authors.initials: S
authors.lastname: Schmidt
authors.forename: Tobias
authors.initials: T
authors.lastname: Schneider
authors.forename: Ingo
authors.initials: I
authors.lastname: Schmidt-Wolf
authors.forename: Yon
authors.initials: Y
authors.lastname: Ko
authors.forename: Uwe
authors.initials: U
authors.lastname: Schlegel
authors.forename: Thomas
authors.initials: T
authors.lastname: Klockgether
authors.forename: Hans-Jörg
authors.initials: HJ
authors.lastname: Hertfelder
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000368:Aged; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010265:Paraproteinemias / Q000097:blood / Q000150:complications*; D015843:Serpins / Q000097:blood* / Q000172:deficiency
chemical_list: D000276:Adjuvants, Immunologic; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human; D015843:Serpins; D000068576:Interferon beta-1b; D016899:Interferon-beta